Biotech Acquisition Gross Profit

The latest gross profit for BIOT is $-5M as of September 2022. That compares with $-1.1M in the prior-year period — down 355.4% year over year. That is below the sector sector average of $750M. Investors often review this figure alongside Biotech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIOT's gross profit moved from $-1.1M to $-5M — a 355.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biotech Acquisition's operating scale or balance-sheet position.

Against its sector companies, BIOT currently prints $-5M for gross profit, while the sector average sits near $750M. That is roughly 100.7% below the sector mean. Large gaps often invite a closer look at Biotech Acquisition's growth, margins, and balance sheet.

A gross profit figure of $-5M for BIOT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $750M. Explore the charts below for those layers of context.

After noting BIOT's gross profit ($-5M), review year-over-year change from $-1.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.